Destiny Pharma PLC - clinical stage biotechnology - To make clinical protocol amendment has been agreed with US Food & Drug Administration for ongoing phase 2b study of lead asset XF-73. Study is evaluating XF-73 as nasal gel for prevention of post-surgical hospital infections caused by staphylococcus aureus bacteria, such as MRSA. Amendment includes change to primary patient population where primary endpoint for the study will be measured, Study size reduced to 125 from 200.
Current stock price: 29.50 pence
Year-to-date change: down 31%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)